publication date: Aug. 7, 2015
20150807 - Aug. 7, 2015
ISSUE 31 – AUG. 7, 2015PDF

Conversation with The Cancer Letter

AstraZeneca Exec Discusses Iressa’s Future in the U.S.

 

After a decade of near-absence from the U.S. market, the AstraZeneca drug Iressa (gefitinib) is back.

The drug, which stayed on the market between 2003 and 2005, when it was pulled because clinical trials in a general population of patients failed to demonstrate a survival advantage, has returned. Now it is accompanied by a diagnostic tests that selects patients.

The Cancer Letter asked Andrew Coop, vice president of US medical affairs in oncology at AstraZeneca, to discuss the company’s plans for the future of Iressa in the US, and lessons that have been learned.

 

Report: Part D Drug Prices “Needlessly High”

Medicare’s Part D program paid significantly higher prices for drugs than either Medicaid or the Veterans Health Administration, a study by Carleton University and Public Citizen found.

Prices paid by Medicare Part D were also above those in 30 other countries.

The price is caused by congressional restrictions on the federal government’s ability to negotiate with the pharmaceutical industry, the study said.

Obituary

Carolyn Kaelin, 54, Dana-Farber Surgical Oncologist and Researcher

Carolyn Mary Kaelin, a surgical oncologist in the Women’s Cancers Program at Dana-Farber and director of the Breast Clinic at Brigham and Women’s Hospital, died July 28, surrounded by loved ones. Kaelin was 54.

FDA News

In Brief

  • Lehigh Valley Health Network joins MSK Cancer Alliance

  • Siteman Cancer Center receives “exceptional” rating from NCI
  • John Cunningham named chairman of pediatrics department at the University of Chicago

  • Jinhgui Zhang named first chair of Department of Computational Biology at St. Jude
  • Stephen Lessnick named director of childhood cancer center at Research Institute at Nationwide Children’s Hospital

  • GI Chair Lopa Mishra to leave MD Anderson Cancer Center

  • Leukemia & Lymphoma Society receives donation from Bristol Myers Squibb

  • Commission on Cancer names Outstanding Achievement Award winners

  • California Dept. of Public Health launches big data collaboration with St. Joseph’s Health

  • Pan-Mass Challenge raises $33.5 million over weekend bike ride for Dana-Farber

 Drugs and Targets

  • Health Canada approves Imbruvica in MCL

  • EMA grants orphan designation to synthetic hypericin
  • AstraZeneca and Heptares Therapeutics enter licensing agreement

  • Mirati Therapeutics and MedImmune launch clinical trial collaboration
 

The Cancer Letter will be taking a short publication break, and will return Friday, Sept. 4.

Copyright (c) 2020 The Cancer Letter Inc.